Servier Research Deals Suggest Business-As-Usual For Scandal-Ridden Firm
This article was originally published in The Pink Sheet Daily
Executive Summary
Still reeling from the Mediator scandal, Servier's two latest cancer research deals suggest the French company is trying to move forward.
You may also be interested in...
With Celgene Deal, Forma Makes First Foray Into Clinical Development
Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.
Lacking "Mediator," EC Tightens Pharmacovigilance Proposals
European Commission's surprise update of the pharmacovigilance rules is included in its review of the information to patients legislation, but industry's biggest concern may be the failure to address the role of social media.
U.K. Newco Raises £6 Mil. To Discover Ubiquitin-Targeting Cancer Drugs
Cancer-focused Mission Therapeutics attracts £6 million Series A, including corporate VC.